Adjuvant single agent chemotherapy in the management of glioblastoma multiforme in Kasr El Aini center of radiation oncology and nuclear medicine, Cairo university Nemrock

ABSTRACT

Adjuvant chemotherapy in the form of single agent CCNU 120 mg/m.S.A. every 6 weeks for 6 cycles conditioned to patients haemopoitic reserve was applied in 35 cases. A response rate of 66.7% and 18 months survival of 41% compared to 50% response rate and 17%, 18 months survival in the other arm of surgery and radiation therapy only. A retrospectively clinicoepidemiological study of 109 cases of glioblastoma multiforme treated in "NEMROCK [1982-1986] was done. The relative frequency incidence was 1.2%. It accounted for 23.2% of primary CNS tumours and 32.8% of all malignant gliomas. The mean age incidence was 32 +/- 17.1 years. The male to female sex ratio was 21. 79.8% of the lesions were in the supratentorial region. Symptoms of increased I.C.P were commonest symptoms and were met within in 86.2% whereas epileptic seizures were the least frequent in 11% of cases